Changing Population Demographics and Treatment Trends Require Continuous Reprioritization of Target Markets for Sales and Marketing Teams

This white paper describes how regional and indication-specific factors have driven changes in the opportunity population for ten diseases between 2008 and 2009 and how these changes have re-prioritized target MSAs. The ten diseases under examination have high prevalence rates and most require chronic treatment. Therefore, these diseases have become high-value targets for pharmaceutical manufacturers.